June 2004

Jane S. Ricciuti, RPh, MS

June 11, 2004

Introduction

The US Food and Drug Administration (FDA) approved Vidaza (azacitidine) as an orphan drug for the treatment of patients with myelodysplastic syndrome. Additional oncology drug approvals include new indications for Gemzar (gemcitabine), Iressa (gefitinib), and Taxotere (docetaxel).

This month's column reviews FDA new product approvals and labeling changes for:

Analgesic Agents

DepoDur (morphine sulfate extended-release liposome) Injection

Anti-Infective Agents

Avelox (moxifloxacin) Tablets and Injection

Antineoplastic Agents

Gemzar (gemcitabine) Injection
Iressa (gefitinib) Tablets
Taxotere (docetaxel) Injection
Vidaza (azacitidine) Injection

Surgical Agents

Vitrase (hyaluronidase) Injection

1 2 3 4 5

Next Section

Cite this: June 2004 - Medscape - Jun 16, 2004.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

June 2004

Introduction

Tables

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback